

Multicentre randomised trial of High dose versus Low dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation following surgery for differentiated thyroid cancer

Submission date 14/06/2006	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 11/09/2006	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 19/10/2018	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-at-radioactive-iodine-treatment-for-thyroid-cancer>

Contact information

Type(s)

Scientific

Contact name

Mr Pablo Alvarez

Contact details

Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
United Kingdom
W1T 4TJ
-
pa@ctc.ucl.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00415233

Protocol serial number

BRD/05/83

Study information

Scientific Title

Multicentre randomised trial of High dose versus Low dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation following surgery for differentiated thyroid cancer

Acronym

HiLo

Study objectives

1. To examine whether a low administrative dose (1.1 GBq) of radioiodine has a similar remnant ablation success rate as a high dose (3.7 GBq)
2. To examine whether patients given recombinant human Thyroid Stimulating Hormone (rhTSH) have a similar ablation success rate to those who discontinue thyroid hormone replacement

Ethics approval required

Old ethics approval format

Ethics approval(s)

Cambridgeshire 4 Research Ethics Committee, 14/07/2006, ref: 06/MRE05/39

Primary study design

Interventional

Study design

Factorial randomised trial (a trial of equivalence)

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Differentiated thyroid cancer

Interventions

Following surgery, eligible patients will be approached for consent. Those who agree will be randomised to one of the following groups:

Group A: rhTSH followed by 1.1 GBq of radioiodine ablation

Group B: rhTSH followed by 3.7 GBq of radioiodine ablation

Group C: Hormone withdrawal (i.e., no rhTSH) followed by 1.1 GBq of radioiodine ablation

Group D: Hormone withdrawal (i.e., no rhTSH) followed by 3.7 GBq of radioiodine ablation

Intervention Type

Mixed

Primary outcome(s)

The percentage of patients who have a successful remnant ablation six to eight months after radioiodine administration

Key secondary outcome(s)

1. Quality of life during treatment period
2. Loco-regional recurrence
3. Distant metastases

Long term outcomes:

1. Survival and incidence of secondary primary malignancies

Completion date

01/09/2010

Eligibility**Key inclusion criteria**

1. Histological confirmation of differentiated thyroid carcinoma
2. Patients with tumour stage pT1-T3; NX, N0 or N1; M0 (TNM Classification of Malignant Tumours 6th edition 2002)
3. Patients who have undergone total thyroidectomy with or without lymph node dissection
4. Patients who require radioiodine ablation
5. Aged 16 to 80 years
6. World Health Organization (WHO) performance status zero to two (self caring)
7. All known tumour resected (R0)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Hurthle cell carcinoma and aggressive variants including tall cell, insular, poorly differentiated, diffuse sclerosing and widely invasive subtypes; anaplastic and medullary carcinoma
2. Patients who have a contrast Computed Tomography (CT) scan up to three months before ablation
3. Patients for whom rhTSH requirement is mandatory
4. Patients who have severe co-morbid conditions (e.g., unstable angina, recent heart attack or stroke, severe labile hypertension, dementia, on dialysis, with tracheostomy needing care, learning difficulties and anybody who may not be able to comply with radiation protection issues or need frequent nursing/medical supervision which puts staff at risk of unacceptable radiation exposure)

5. Other cancers excluding basal cell carcinoma of the skin or in situ carcinoma of the cervix
6. Pregnant women or women who are breastfeeding
7. Patients with stage pT4 or M1 (if detected clinically or by other investigations)
8. Previous 131I or 123I pre-ablation scan
9. Previous treatment for thyroid cancer (except surgery)

Date of first enrolment

01/01/2007

Date of final enrolment

31/07/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Cancer Research UK & UCL Cancer Trials Centre

London

United Kingdom

W1T 4TJ

Sponsor information

Organisation

University College London (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Research organisation

Funder Name

Cancer Research UK (CRUK) (UK) - Clinical Trials Advisory and Awards Committee (CTAAC)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	03/05/2012		Yes	No
Plain English results				No	Yes